← Back to Search

Enasidenib for Acute Myeloid Leukemia

Phase 1
Recruiting
Led By Amandeep Salhotra
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x ULN, patients with abnormal liver function tests (LFTs) in the context of active GVHD will not be included (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
Eastern Cooperative Oncology Group (ECOG) =< 2 or Karnofsky performance status (KPS) >= 70
Must not have
Females only: Pregnant or breastfeeding
Active infection requiring antibiotics
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from starting enasidenib to date of death, assessed up to 2 years
Awards & highlights

Summary

This trial is testing if enasidenib is a safe and effective maintenance therapy for patients with acute myeloid leukemia who have had a donor stem cell transplant.

Who is the study for?
This trial is for adults with acute myeloid leukemia (AML) and an IDH2 mutation who've had a donor stem cell transplant. They must not be pregnant, have good organ function, no severe active infections or other cancers, and agree to birth control. People with Gilbert's disease or uncontrolled illnesses can't join.
What is being tested?
Enasidenib Mesylate is being tested as a maintenance therapy for AML patients post-stem cell transplant. The study aims to see if this drug can prevent cancer growth by inhibiting certain enzymes needed by cancer cells.
What are the potential side effects?
Possible side effects of Enasidenib include liver problems, blood disorders, fatigue, nausea, diarrhea, joint pain and may affect heart rhythm which will be closely monitored during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My liver function tests are normal or near normal.
Select...
I am mostly self-sufficient and can carry out daily activities.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
I am currently taking antibiotics for an infection.
Select...
I am currently being treated with steroids for acute GVHD.
Select...
I have severe diarrhea that could affect taking medication by mouth.
Select...
I have a serious health condition that is not under control.
Select...
I have been diagnosed with Gilbert's disease.
Select...
I have a history of HIV, hepatitis B, or hepatitis C.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from starting enasidenib to date of death, assessed up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from starting enasidenib to date of death, assessed up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events (AEs)
Secondary study objectives
Graft versus host disease (GvHD)-free relapse free survival (GRFS)
Leukemia free survival (LFS)
Non-relapse mortality (NRM)
+2 more
Other study objectives
IDH2 mutation clearance (BM and peripheral blood)
Minimal residual disease (MRD) disappearance (bone marrow [BM])
mIDH2 variant allele fraction (BM)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (enasidenib mesylate)Experimental Treatment1 Intervention
Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,858 Previous Clinical Trials
41,006,699 Total Patients Enrolled
City of Hope Medical CenterLead Sponsor
596 Previous Clinical Trials
1,923,437 Total Patients Enrolled
Amandeep SalhotraPrincipal InvestigatorCity of Hope Medical Center
4 Previous Clinical Trials
93 Total Patients Enrolled
~10 spots leftby Jan 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top